goodrx holdings inc. - GDRX
GDRX
Close Chg Chg %
4.49 0.07 1.56%
Closed Market
4.56
+0.07 (1.56%)
Volume: 4.47M
Last Updated:
Aug 22, 2025, 4:00 PM EDT
Company Overview: goodrx holdings inc. - GDRX
GDRX Key Data
| Open $4.49 | Day Range 4.49 - 4.73 |
| 52 Week Range 3.31 - 8.80 | Market Cap $1.56B |
| Shares Outstanding 347.45M | Public Float 81.17M |
| Beta 1.24 | Rev. Per Employee N/A |
| P/E Ratio 48.38 | EPS $0.09 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 5.04M |
GDRX Performance
| 1 Week | 22.25% | ||
| 1 Month | -8.80% | ||
| 3 Months | 21.93% | ||
| 1 Year | -44.59% | ||
| 5 Years | N/A |
GDRX Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
17
Full Ratings ➔
An error occurred while fetching the data.
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Goodrx Holdings Inc. - GDRX
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 745.42M | 766.55M | 750.26M | 792.32M | |
Sales Growth
| +35.36% | +2.83% | -2.12% | +5.61% | |
Cost of Goods Sold (COGS) incl D&A
| 81.25M | 118.81M | 170.09M | 117.75M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 37.64M | 57.53M | 111.77M | 69.54M | |
Depreciation
| 7.10M | 7.95M | 8.90M | 4.50M | |
Amortization of Intangibles
| 30.54M | 49.58M | 102.87M | 65.04M | |
COGS Growth
| +69.22% | +46.22% | +43.16% | -30.77% | |
Gross Income
| 664.17M | 647.74M | 580.17M | 674.57M | |
Gross Income Growth
| +32.12% | -2.47% | -10.43% | +16.27% | |
Gross Profit Margin
| +89.10% | +84.50% | +77.33% | +85.14% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 636.47M | 610.58M | 528.80M | 585.28M | |
Research & Development
| 125.86M | 138.88M | 133.44M | 123.75M | |
Other SG&A
| 510.61M | 471.70M | 395.36M | 461.53M | |
SGA Growth
| -17.35% | -4.07% | -13.39% | +10.68% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 14.30M | 46.83M | 77.03M | 25.52M | |
EBIT after Unusual Expense
| 13.41M | (9.67M) | (25.65M) | 63.77M | |
Non Operating Income/Expense
| 59.00K | 20.68M | 26.81M | 20.61M | |
Non-Operating Interest Income
| 59.00K | 9.27M | 32.17M | 23.27M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 23.64M | 34.24M | 56.73M | 52.92M | |
Interest Expense Growth
| -15.30% | +44.84% | +65.66% | -6.71% | |
Gross Interest Expense
| 23.64M | 34.24M | 56.73M | 52.92M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (10.18M) | (23.23M) | (55.57M) | 31.46M | |
Pretax Income Growth
| +96.65% | -128.27% | -139.21% | +156.61% | |
Pretax Margin
| -1.37% | -3.03% | -7.41% | +3.97% | |
Income Tax
| 15.08M | 9.60M | (46.70M) | 15.07M | |
Income Tax - Current - Domestic
| 2.17M | 10.09M | 18.86M | 26.98M | |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| 12.91M | (497.00K) | (65.56M) | (11.91M) | |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (25.25M) | (32.83M) | (8.87M) | 16.39M | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (25.25M) | (32.83M) | (8.87M) | 16.39M | |
Net Income Growth
| +91.40% | -29.99% | +72.99% | +284.82% | |
Net Margin Growth
| -3.39% | -4.28% | -1.18% | +2.07% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (25.25M) | (32.83M) | (8.87M) | 16.39M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (25.25M) | (32.83M) | (8.87M) | 16.39M | |
EPS (Basic)
| -0.063 | -0.0795 | -0.0216 | 0.0425 | |
EPS (Basic) Growth
| +91.60% | -26.19% | +72.83% | +296.76% | |
Basic Shares Outstanding
| 400.56M | 412.86M | 410.31M | 385.74M | |
EPS (Diluted)
| -0.063 | -0.0795 | -0.0216 | 0.0418 | |
EPS (Diluted) Growth
| +91.60% | -26.19% | +72.83% | +293.52% | |
Diluted Shares Outstanding
| 400.56M | 412.86M | 410.31M | 392.17M | |
EBITDA
| 65.34M | 94.69M | 163.15M | 158.83M | |
EBITDA Growth
| +126.73% | +44.90% | +72.30% | -2.65% | |
EBITDA Margin
| +8.77% | +12.35% | +21.75% | +20.05% |
An error occurred while fetching the data.
SEC Filings for Goodrx Holdings Inc. - GDRX
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Goodrx Holdings Inc. - GDRX
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Jul 10, 2025 | Ian T. Clark Director | 34,497 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jul 10, 2025 | Ian T. Clark Director | 100,150 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $4.74 per share | 474,711.00 |
| Mar 24, 2025 | Idea Men LLC Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 Non-derivative transaction at $4.2 per share | 0.00 |
| Mar 24, 2025 | Idea Men LLC Director | 7,000,000 | Conversion of derivative security | 0.00 |
| Mar 17, 2025 | Scott W. Wagner Director | 253,618 | Bona fide gift | 0.00 |
| Mar 17, 2025 | Scott W. Wagner Director | 189,386 | Bona fide gift | 0.00 |
| Mar 17, 2025 | Scott W. Wagner Director | 125,154 | Bona fide gift | 0.00 |
| Mar 11, 2025 | Romin Nabiey Chief Accounting Officer | 26,787 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 11, 2025 | Romin Nabiey Chief Accounting Officer | 61,205 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 11, 2025 | Romin Nabiey Chief Accounting Officer | 106,874 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $4.61 per share | 492,689.14 |
| Mar 11, 2025 | Romin Nabiey Chief Accounting Officer | 107,682 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 11, 2025 | Romin Nabiey Chief Accounting Officer | 105,449 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $4.61 per share | 486,119.89 |
| Mar 11, 2025 | Romin Nabiey Chief Accounting Officer | 109,640 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 6, 2025 | Christopher A. McGinnis See Remarks | 1,096,937 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Christopher A. McGinnis See Remarks | 716,479 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Wendy Barnes See Remarks; Director | 2,828,232 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Wendy Barnes See Remarks; Director | 409,416 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Wendy Barnes See Remarks; Director | 1,842,374 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 24, 2025 | Scott W. Wagner Director | 94,182 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 6, 2025 | Ronald Earl Bruehlman Director | 32,284 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
Goodrx Holdings Inc. in the News
Novo Nordisk to sell weight-loss drug for $499 to eligible customers
Cash-paying type 2 diabetes patients in the United States can now access Novo Nordisk's Ozempic for $499 per month through multiple pharmacy platforms.